Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs
Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.
/ 919 items
#Healthcare↓
Evoke Pharma Shares Double Following Agreement to Be Acquired by QOL Medical for $11 Per Share
QOL Medical buys Evoke Pharma for $11/share (140% premium). Evoke sells GIMOTI, a key nasal spray for diabetic stomach issues.
Pfizer's Q3: Profit Boosted by Cost Cuts Amidst Major Obesity Acquisition Battle
Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
Sarepta Therapeutics Shares Crash 40% After Key Drug Trial Fails to Show Benefits
Sarepta Therapeutics stock plunges as confirmatory trial for DMD drugs misses primary endpoint, adding to company's recent setbacks including Elevidys safety concerns.
Hims & Hers Shares Jump on Talks With Novo Nordisk, Strong Q3 Results
Hims & Hers Health rose in after-hours trading after revealing talks with Novo Nordisk about offering Wegovy’s new obesity pill. The telehealth firm also beat Q3 revenue estimates, reporting nearly $600 million in sales and strong subscriber growth.
DOJ Probes Regencell Bioscience After 46,000% Stock Surge
The US Department of Justice is investigating Regencell Bioscience’s extreme stock volatility after its shares skyrocketed 46,000%, prompting questions over trading activity.